What's in Goldman, Butterwick, Fitzpatrick and Groff's pipeline?

Goldman, Butterwick, Fitzpatrick and Groff has 11 drugs in our index: 6 marketed, 0 filed, 1 in Phase 3, 4 in Phase 2, 0 in Phase 1.

Which companies overlap with Goldman, Butterwick, Fitzpatrick and Groff's portfolio?

Top competitors by shared drug class: AAADRS Clinical Research Center, Actavis Inc., Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona, Brian J Lipworth, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/goldman-butterwick-fitzpatrick-and-groff.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Goldman, Butterwick, Fitzpatrick and Groff — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Goldman, Butterwick, Fitzpatrick and Groff pipeline: 6 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Inggenol Mebutate 0.015%	Inggenol Mebutate 0.015%	marketed	Protein kinase C activator	Protein kinase C (PKC)	Dermatology
air cooling	air cooling	marketed
Injectable sodium deoxycholate	Injectable sodium deoxycholate	marketed
Barrier Renew	Barrier Renew	marketed
Sodium Deoxycholate	Sodium Deoxycholate	marketed	Lipid-dissolving agent / Lipolytic agent	Adipocyte cell membrane	Dermatology / Aesthetics
Antihistamine Cetirizine Hydrochloride	Antihistamine Cetirizine Hydrochloride	marketed	H1-receptor antagonist (second-generation antihistamine)	H1 histamine receptor	Immunology / Allergy
enhanced DefenAge 8-in-1 BioSerum	enhanced DefenAge 8-in-1 BioSerum	phase 3	topical anti-aging agent		Dermatology

Therapeutic area mix

Dermatology · 3
Dermatology / Aesthetics · 1
Immunology / Allergy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AAADRS Clinical Research Center · 1 shared drug class
Actavis Inc. · 1 shared drug class
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona · 1 shared drug class
Brian J Lipworth · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
HK inno.N Corporation · 1 shared drug class
LEO Pharma · 1 shared drug class
Neal D. Bhatia, MD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Goldman, Butterwick, Fitzpatrick and Groff:

Cite this brief

Drug Landscape (2026). Goldman, Butterwick, Fitzpatrick and Groff — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/goldman-butterwick-fitzpatrick-and-groff. Accessed 2026-05-17.